<DOC>
	<DOCNO>NCT01130506</DOCNO>
	<brief_summary>This phase I trial study side effect best dose cytarabine give together decitabine vorinostat treat patient relapsed refractory acute myeloid leukemia . Drugs use chemotherapy , cytarabine decitabine , work different way stop growth cancer cell , either kill cell stop dividing . Vorinostat may stop growth cancer cell block enzymes need cell growth . Giving cytarabine together decitabine vorinostat may kill cancer cell .</brief_summary>
	<brief_title>Decitabine , Vorinostat , Cytarabine Treating Patients With Relapsed Refractory Acute Myeloid Leukemia</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine maximum tolerate dose ( MTD ) combination decitabine , vorinostat , cytarabine patient relapsed/refractory acute myeloid leukemia ( AML ) select subset high risk leukemia/myelodysplastic syndrome ( MDS ) . II . To define specific toxicity dose limit toxicity ( DLT ) combination . SECONDARY OBJECTIVES : I . To develop platform specifically target MLL PTD , future efficacy study . II . To determine overall response rate ( ORR ) regimen relapsed/ refractory AML . III . To examine role decitabine vorinostat re-expression MLL- WT patient MLL PTD via correlative study specific patient MLL PTD preliminary relationship clinical response patient MLL PTD+ AML . IV . To correlate biological activity decitabine demethylating agent ( change target gene methylation gene expression , DNMT1 protein expression , global methylation ) clinical endpoint V. To explore biologic role microRNAs determine clinical response combination achievement pharmacodynamic endpoint . OUTLINE : This dose-escalation study cytarabine . INDUCTION THERAPY : Patients receive decitabine IV 1 hour day 1-10 ; oral vorinostat day 5-10 ; high-dose cytarabine IV 2 hour day 12 , 14 , 16 absence disease progression unacceptable toxicity . Patients achieve complete response ( CR ) proceed maintenance therapy . Patients achieve CR incomplete blood count recovery undergo bone marrow aspiration biopsy count recovery day 42 proceeding maintenance therapy . MAINTENANCE THERAPY : Patients receive decitabine IV 1 hour day 1-5 oral vorinostat day 5-10 . Treatment repeat every 28 day 11 course absence disease progression unacceptable toxicity . Blood sample additional bone marrow aspirate biopsy collect baseline study re-expression mixed lineage leukemia-wild-type , change target gene methylation gene expression , DNMT1 protein expression , global methylation , pharmacodynamic study . After completion study therapy , patient follow 30 day .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Leukemia , Promyelocytic , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Decitabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<criteria>Diagnosis acute myeloid leukemia ( AML ) Relapsed refractory disease Secondary AML therapy related disease ( tAML ) allow AML mixedlineage leukemia partialtandem duplication ( MLL PTD ) No advanced malignant solid tumor additional active hematologic malignancies No active CNS disease granulocytic sarcoma sole site disease ECOG performance status 02 Life expectancy &gt; 6 month ( patient comorbid medical illness ) Total bilirubin &lt; 2.0 mg/dL AST and/or ALT 2.5 time upper limit normal Creatinine &lt; 2.0 mg/dL Not pregnant nursing Negative pregnancy test Fertile patient must agree use effective contraception study therapy Known HIV infection allow provide follow criterion meet : No history AIDS High CD4 cell count ( &gt; 400/mm^3 ) Low HIV viral load ( &lt; 30,000 copies/mL plasma ) No requirement antiHIV therapy No history medically serious allergic reaction attribute decitabine , vorinostat , cytarabine , compound similar chemical biologic composition easily manage No uncontrolled intercurrent illness include , limited , follow : Symptomatic congestive heart failure Unstable angina pectoris Serious cardiac arrhythmia Psychiatric illness social situation would limit compliance study requirement Myocardial infarction within past 6 month NYHA class IIIIV heart failure Severe uncontrolled ventricular arrhythmia Electrocardiographic evidence acute ischemia active conduction system abnormalities Medical comorbidities would preclude safety evaluation combination therapy No serious medical psychiatric illness likely interfere participation clinical study No history neurologic toxicity attribute cytarabine vorinostat Active infection control allow Patients uncontrolled infection shall enrol treated brought control Able swallow pill Prior decitabine azacitidine myelodysplastic syndrome AML allow Prior highdose cytarabine ( &gt; 1 g/m²/dose ) allow More 2 week since prior chemotherapy ( 6 week nitrosoureas mitomycin C ) radiotherapy recover toxicity &lt; grade 2 More 2 week since valproic acid histone deacetylase inhibitor More 14 day since prior concurrent investigational agent No concurrent antiHIV therapy No concurrent warfarin Coumadin® derivative No concurrent anticancer agent therapies No concurrent palliative radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>June 2014</verification_date>
</DOC>